July 7 (Reuters) - Obesity-focused clinical-stage biotechnology company Kalohexis on Tuesday confidentially filed to go public in the U.S., adding to an activity rebound in the initial public offering ...

Vertex Pharmaceuticals is buying an endocrine treatment specialist for $10 billion.

Eupraxia Pharmaceuticals Inc. ('Eupraxia' or the 'Company') (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize ...

Seeking biotech investment, breakthrough innovations, or a strategic gateway to the Asia-Pacific? The answers await in Hong Kong this September.HONG KONG, July 7, 2026 /PRNewswire/ -- The 5th Hong ...

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. Syndax Pharmaceuticals, ...

Following an independent salary analysis, this landmark certification sets a benchmark for data-driven pay equity and ...

Novartis has acquired UK biotech Myricx for up to $1.5bn as global drugmakers invest inpromising biotech firms ahead expected ...

Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging ...

Brandon Capital will receive more than $300 million from the sale of Myricx, which is developing cancer-killing “biological ...

Biotechnology investors often focus on clinical milestones, regulatory approvals, and commercial launches. Yet in antibody ...

Three mid-cap biotechs have become prime acquisition targets, but only one offers what big pharma is hunting for most.

Ligand Pharma (LGND) stock jumped in the final week of June, but the proximate cause was the pricing of $625M of convertible ...